Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Beyond biomarkers: tissue still matters.

The Lancet. Haematology·2026
Same author

SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England)·2026
Same author

Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

British journal of haematology·2026

Related Experiment Video

Updated: Jul 3, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Angioimmunoblastic T-cell lymphoma.

Emilio Iannitto1, Andrés J M Ferreri, Viviana Minardi

  • 1Division of Hematology, High Dose Therapy Unit, Policlinico Paolo Giaccone, Palermo, Italy.

Critical Reviews in Oncology/Hematology
|August 8, 2008
PubMed
Summary
This summary is machine-generated.

Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive cancer with poor prognosis. Early detection and treatment, including stem cell transplant and immunosuppressants, may improve outcomes for AITL patients.

More Related Videos

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

Related Experiment Videos

Last Updated: Jul 3, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare, aggressive T-cell neoplasm.
  • Clinical features include constitutional symptoms, lymphadenopathy, hepatosplenomegaly, autoimmune phenomena (hemolytic anemia, thrombocytopenia), and hypergammaglobulinemia.
  • Histopathology reveals a polymorphic infiltrate, prominent high endothelial venules, and dendritic cells, with neoplastic CD4+ T-cells often expressing CD10.

Purpose of the Study:

  • To summarize the clinical, histological, and prognostic features of Angioimmunoblastic T-cell lymphoma.
  • To highlight diagnostic markers and treatment strategies for AITL.

Main Methods:

  • Review of clinical and pathological data from AITL cases.
  • Analysis of diagnostic markers, including CD10 expression on neoplastic T-cells.
  • Evaluation of treatment outcomes and prognostic factors.

Main Results:

  • AITL is characterized by distinct clinical and histological findings.
  • Neoplastic CD4+ T-cells are a minority but identifiable by CD10 expression.
  • Most AITL cases involve Epstein-Barr virus (EBV)-infected B-cells.
  • Conventional treatment yields a poor prognosis (median survival < 3 years).

Conclusions:

  • High-dose therapy with autologous stem cell transplantation may benefit patients with a good clinical response.
  • Immunosuppressive/immunomodulatory agents like thalidomide can manage constitutional symptoms, autoimmune phenomena, and neoplastic masses.